retatrutide triple agonist gip glp-1 glucagon just changed the conversation around weight loss medication. This (GLP-1 + + glucagon) is still in Phase 3 trials, but Phase 2 data showed 24.2% body weight loss Direct Meds vs. Shed active_products_260330 Quantity:30 CT (1 Bottle)

retatrutide triple agonist gip glp-1 glucagon just changed the conversation around weight loss medication. This (GLP-1 + + glucagon) is still in Phase 3 trials, but Phase 2 data showed 24.2% body weight loss Direct Meds vs. Shed active_products_260330 Quantity:30 CT (1 Bottle)

Direct Meds vs. Shed vs. Refills: Comparing the Flat-Price GLP-1 Programs | Newswire

"Whether we'd like to admit it or not, our appearance matters," says Sarwer

active_products_260330

Quantity:30 CT (1 Bottle)

market share—60.9% to 38.8% as of August—driven partly by its rival obesity drug, Zepbound, and an oral pill in development that Goldman Sachs projects could capture 60% of the daily-pill segment by 2030